Medinet Co Ltd
TSE:2370

Watchlist Manager
Medinet Co Ltd Logo
Medinet Co Ltd
TSE:2370
Watchlist
Price: 40 JPY Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Medinet Co Ltd?
Write Note

Medinet Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Medinet Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Medinet Co Ltd
TSE:2370
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CMIC Holdings Co Ltd
TSE:2309
Current Portion of Long-Term Debt
ÂĄ1B
CAGR 3-Years
-32%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
C
Chiome Bioscience Inc
TSE:4583
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Precision System Science Co Ltd
TSE:7707
Current Portion of Long-Term Debt
ÂĄ277m
CAGR 3-Years
11%
CAGR 5-Years
2%
CAGR 10-Years
-7%
CellSource Co Ltd
TSE:4880
Current Portion of Long-Term Debt
ÂĄ20.3m
CAGR 3-Years
85%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WDB coco Co Ltd
TSE:7079
Current Portion of Long-Term Debt
ÂĄ13.2m
CAGR 3-Years
29%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Medinet Co Ltd
Glance View

Market Cap
10.3B JPY
Industry
Life Sciences Tools & Services

MEDINET Co., Ltd. engages in cell processing business. The company is headquartered in Ota-Ku, Tokyo-To and currently employs 83 full-time employees. The company went IPO on 2003-10-08. The company operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. The company also provides comprehensive support services for immune cell therapy.

Intrinsic Value
7.7 JPY
Overvaluation 81%
Intrinsic Value
Price

See Also

Back to Top